AIM
TVRD

Axiom Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Axiom Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Buy
+1
New +$3 ﹤0.01% 526
2022
Q4 		– Sell
-1
Closed – – 443
2022
Q3 		$0 Buy
+1
New +$362 ﹤0.01% 466

Other funds holding TVRD

DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Axiom Investment Management's TVRD Position: Q2 2026 in Review

Axiom Investment Management opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #526 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in TVRD as recently as Q3 2022.

Axiom Investment Management first reported a position in TVRD in Q3 2022 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Axiom Investment Management held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
  • Tvardi Therapeutics was a new Axiom Investment Management position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #526 holding.
  • Axiom Investment Management first reported a position in Tvardi Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.